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SUMMARY. Vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) are key factors in physiologi-
cal and pathological conditions of pregnancy. We investigated whether serum levels of PlGF in mother’s and umbilical 
blood are different between healthy pregnant women and pregnant women suffering from type-1 diabetes mellitus. We 
performed a prospective study of 44 pregnant women with type 1 diabetes who did not have diabetic complications and 
of 34 healthy pregnant women of the adequate age and parity and the normal pregnancy course. Venous blood samples 
were collected from 8th weeks of pregnancy during the whole pregnancy, in distance from 4 weeks. Results are expressed 
as means±standard deviations. Statistical analysis was performed using ANOVA, Student t-test, linear regression, and 
non-parametrical Mann-Whitney U test. PlGF level in diabetic and healthy pregnant women from the 8th till the 15th week 
of pregnancy is comparatively low (23.16±4.94 pg/mL : 21.68 ±4.91 pg/mL), and after the 15th week of pregnancy it in-
creases fast till the 31st week of pregnancy when the value is the highest (440.77±173.03 pg/ml : 390.41±138.07 pg/mL). 
After the 31st week of pregnancy there is a decrease of PlGF levels. Comparing PlGF values between the research groups 
in defined weeks of pregnancy no statistically significant difference was found. PlGF values in serum of healthy and 
diabetic pregnant women do not differ in same weeks of pregnancy. PlGF values in mother’s and fetal serum immedia-
tely after the birth are a bit lower (but not statistically significant) in diabetic pregnant women in relation to a control 
group. A statistically significant correlation coefficient was found between PlGF level and a newborns weight and be-
tween PlGF and placenta weight. A statistically significant correlation coefficient was found between PlGF level of 
mother’s blood and umbilical vein.
Izvorni ~lanak
Klju~ne rije~i: Placentarni ~imbenik rasta, dijabeti~na trudno}a
SA`ETAK. Vaskularni endotelni ~imbenik rasta (VEGF) i placentarni ~imbenik rasta (PlGF) su klju~ni ~imbenici u 
fiziolo{kim i patolo{kim trudno}ama. Cilj istra`ivanja je bio na}i razliku razina PlGF-a u maj~inoj i umbilikalnoj krvi 
izme|u zdravih trudnica i onih koje boluju od dijabetsa tipa-1. U~injeno je prospektivno istra`ivanje u 44 trudnice s 
dijabetesom tipa-1 i u 34 zdrave trudnice. Trudnice su bile istih dobnih skupina, pariteta i urednog tijeka trudno}e. Ven-
ska krv trudnica je skupljana od 8. tjedna trudno}e tijekom cijele trudno}e u vremenskim razmacima od 4 tjedna. Rezul-
tati su prikazani srednjim vrijednostima ± standardne devijacije, a statisti~ka analiza je u~injena sljede}im testovima: 
ANOVA, Student-t testom, linearnom regresijom i Mann-Whitneyevim U testom. Razina PlGF-a u dijabeti~nih i zdravih 
trudnica je bila podjednako niska u vremenskom razdoblju od 8. do 15. tjedna trudno}e (23,16±4,94 pg/mL : 21,68±4,91 
pg/mL), a nakon 15. tjedna dolazi do naglog povi{enja razine sve do 31. tjedna trudno}e kada su vrijednosti bile i najvi{e 
(440,77±173,03 pg/ml : 390,41±138,07 pg/mL). Nakon 31. tjedna trudno}e dolazi do sni`enja vrijednosti PlGF-a. 
Uspore|uju}i vrijednosti PlGF-a izme|u istra`ivanih skupina u istim tjednima trudno}e nije na|ena statisti~ki znakovita 
razlika. Neposredno nakon poroda razina PlGF-a u maj~inom i fetalnom serumu je bila ne{to ni`a, ali ne i statisti~ki 
znakovito ni`a u dijabeti~nih trudnica u odnosu na zdrave trudnice. Na|ene su statisti~ki zna~ajne korelacije izme|u 
razina PlGF-a i porodne te`ine, izme|u PlGF-a i te`ine placente i izme|u razina PlGF-a seruma majke i seruma umbi-
likalne vene.
Introduction
The aim of a placenta is to ensure optimal conditions 
for fetal development. That is why normal development 
of placenta is important. The growth of placenta is regu-
lated by a local production of growth factors which act 
by autocrine and paracrine mechanism in order to influ-
ence various cell functions.1 A placenta is situated in 
such a way that it is influenced both by regulatory fac-
tors of mother and a fetus.2
The physiological process of placental development 
includes: (a) forming of blastocyst and trophoblast dif-
ferentiation;1 (b) blastocyst adhesion to decidua; (c) 
 trophoblast invasion; (d) vasculogenesis and angiogen-
esis.
A trophoblast has to pass through the uterus epitheli-
um in order to invade uterus, to reach blood vessels 
which will finally bath chorionic villi. The production 
of specific proteases and their inhibitors which is pre-
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cisely regulated is important for controlled invasion of 
trophoblast in the uterus wall.3,4
On 21 day after ovulation, the major morphological 
features of placenta are developed (tertiary villi built of 
syncytiotrophoblast, cytotrophoblast, loose mesenchy-
me and differentiated blood vessels in it; anchored villi 
and peripheral cytotrophoblast covering).3
A cytotrophoblast which migrates into a decidual part 
of spiral arteries structurally changes these vessels and 
turns them into uteroplacental arteries. A cytotropho-
blast enters a spiral artery in the myometrium area, and 
it can also affect distal parts of radial artery (Fig. 1). 
Morphological changes of spiral artery tunica media 
lead to: a) increased flow of mother’s blood, which is 
the reason of dilation of these vessels in uteroplacental 
arteries; b) loss of muscular-elastic component, so 
uteroplacental arteries can no longer respond to changes 
within the autonomous nervous system.
Trophoblast stoppers close a bigger part of uteropla-
cental artery lumen till the end of the 11th week of devel-
opment.5 Intervillous area is filled by a transparent liq-
uid, similar to mother’s blood plasma, while fetal eryth-
rocytes are in blood vessels of placental villi. In the 12th 
week of development, arteries are completely open, the 
increased amount of mother’s blood enters the intervil-
lous area, and so mother’s erythrocytes appear together 
with blood plasma. From the 12th week, the pulsation 
flow of mother’s blood starts, synchronous with heart 
beats.6
A placenta in its early stages of pregnancy secrets nu-
merous angiogenic factors. However, a trophoblast in 
its early stages of development synthesizes big quanti-
ties of VEGFR-1 (Flt-1) receptor which inhibits angio-
genic factors.7, 8 Turning of spiral arteries into uteropla-
cental blood vessels is completed in the middle of preg-
nancy, while the angiogenesis in placenta and in a fetus 
continues during the whole pregnancy. Numerous vas-
cular endothelial growth factors (VEGF) participate in 
placental angiogenesis which are mostly synthesized by 
cytotrophoblast. Hildebrandt et al.9 proved receptors for 
these factors on the endothelium of blood vessels and 
their number depends on the estrogens level.
Placental growth factor (PlGF) appears in syncytio-
trophoblast and/or cytotrophoblast, in endothelium and 
in middle of blood vessel villi and in decidual cells. Hy-
poxia causes the VEGF concentration increase and de-
creased excretion of PIGF.10,11
Diabetes in pregnancy causes many problems both 
for a mother and a child. Thanks to good metabolic con-
trol of pregnant diabetics, antenatal and neonatal care, 
monitoring the fetal condition by cardiotocography and 
ultrasound, amniotic fluid analysis for proving a fetal 
lung maturity and more liberal attitude to the birth com-
pletion by caesarean section, the perinatal mortality has 
significantly decreased and is insignificantly higher in 
comparison to non-diabetic population.12
The purpose of this study was to examine the level of 
PlGF, in systemic and umbilical bloodstream and their 
progress during pregnancy in healthy pregnant women 
and pregnant women with type-1 diabetes and to deter-
mine differences between healthy pregnant women and 
pregnant women suffering from type-1 diabetes melli-
tus.
Research design and methods
The research was prospective. The research group 
consisted of 44 pregnant women with type 1 diabetes 
who did not have diabetes complications and the control 
group of 34 healthy pregnant women of the adequate 
age and parity and the normal pregnancy course. The 
course of pregnancy was followed by usual antenatal 
care measures (regular obstetrical examinations, labora-
tory tests, ultrasound examinations, CTG). The preg-
nant women with type-1 diabetes treatment included 
advice about diet, adequate insulin therapy to achieve 
normoglycemia, ophthalmologist’s and nephrologist’s 
examination. All pregnant women with type-1 diabetes 
recieve two injections of medium-acting insulin every 12 
hours for keeping basal insulin value in blood and also 
three injections of short-acting insulin immediately before 
main meals by using a syringe in the form of a pencil.
Pregnant women in diabetic and control group who 
developed some complication during pregnancy (hyper-
tension/preeclampsia) were exempted from the sample. 
The gestation age is calculated from the first day of the 
last period, with the correction to the ultrasound age – 
the results of transvaginal ultrasound examination 
(within the routine examination of a pregnant woman). 
Venous blood samples were collected from 8th week of 
pregnancy during the whole pregnancy, in periods from 
4 weeks. Immediately after the birth, the blood sample 
was taken from the umbilical vein and a placenta was 
weighed and sent to pathohistological analysis.
Serum was separated from the vein blood by the usu-
al laboratory procedure (centrifugation at 4000 rpm 
Figure 1. Utero-placental vessel in the myometrium showing adequate 
physiological change (H-E × 160)
Slika 1. Utero placentarna krvna `ila u miometriju pokazuje adekvatnu 
fiziolo{ku promjenu (H-E × 160)
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during 10 minutes, collected supersediment by pipette). 
Serum samples were stored at the temperature of –75°C 
till the moment of testing. Establishing PIGF values in 
samples was carried out by ELISA technique, commer-
cial kit Quantikine (R&D Systems, Minneapolis, USA) 
for human PlGF. Umbilical vein blood samples (0.4 
mL) were drawn into sterile syringes and analyzed for 
measurement pH, pO2 and base excess (BE) with an 
ABL5 blood gas analyzer (Radiometer, Copenhagen, 
Denmark).
Statistical processing was done by a computer pro-
gramme SPSS vers. 10.0, on a personal computer. Data 
are presented as the mean ± standard deviation. In the 
cross-sectional study, comparisons of clinical variables 
and immunoassay data in type-1 diabetes pregnant pa-
tient group were with the respective control group. 
Clinical variables were analyzed with the unpaired Stu-
dent t test. Differences between two groups were esti-
mated by Student t-test, by ANOVA with repeated mea-
sures and non-parametrical Man-Whitney U test. Com-
parisons of PlGF values in mothers and fetal serum and 
newborns weight and placental weight were made by 
regression methods and presented graphically. All tests 
were two tailed, and a probability value of p<.05 was 
considered to be significant.
Results
In a control group of totally 34 births, 22 births were 
completed vaginally and 12 by caesarean section. In 
 research group of totally 44 births 15 birth were com-
pleted vaginally and 29 by caesarean section. All preg-
nancies were completed after the 37th week of preg-
nancy.
Newborn babies and placentas of pregnant women of 
both the research and the control group were of the sim-
ilar weight (Table 1). There was not a significant differ-
ence in the age of pregnant women and the duration of 
pregnancy. Also, there was not a statistically significant 
difference in Apgar score after the first and after the 
fifth minute in two research groups.
Table 1. General data about pregnant women, their newborn babies and 
placentas of research groups.






























Te`ina placente (g) 520.5±105 555.7±154 n.s.
Birth weight
Poro|ajna te`ina (g) 3330.1±552.3 3565.8±603.6 n.s.
Birth length










Table 2. PlGF levels (pg/mL) during pregnancy of research groups.
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pregnancy
Razina PlGF izme|u





Figure 2. Linear correlation between PlGF levels of umbilical vein pla-
sma and PlGF of mother’s plasma (r=0.4; p<0.05)
Grafikon 2. Linearna korelacija izme|u PlGF u plazmi umbilikalne vene 
i PlGF u plazme majke (r=0,4; p<0,05)
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Placental growth factor was determined in both dia-
betic and healthy pregnant women from the 8th week of 
pregnancy till the time of delivery (Table 2). P1GF
level in diabetic and healthy pregnant women from the 
8th till the 15 th week of pregnancy is comparatively low 
(23.16±4.94 pg/mL : 21.68±4.91 pg/mL), and after the 
15th week of pregnancy it increases fast till the 31st week 
of pregnancy when the value is the highest (440.77±
173.03 pg/mL : 390.41±138.07 pg/mL). After the 31st 
week of pregnancy there is a decrease of P1GF level. At 
the time of delivery, P1GF level in the type-1 diabetes 
group is 178.0±191.0 pg/ml; P1GF level in the control 
group is 249.6±193.1 pg/mL. Comparing P1GF values 
between the research groups in defined weeks of preg-
nancy no statistically significant difference was found 
(Table 2).
A statistically significant correlation (r=0.4; p<0.05) 
between the newborn’s weight and P1GF serum of 
mother was found. A statistically significant correlation 
(r=0.5; p<0.05) between the placenta weight and P1GF 
level of umbilical vein was found as well.
There was no difference in P1GF values in relation to 
birth completion method (P1GF level in mothers who 
gave birth by caesarean section was 244.9±188.14 pg/mL 
: 169.3±159.3 pg/mL of P1GF level in mothers who gave 
birth vaginally).
P1GF values in an umbilical vein were lower in rela-
tion to P1GF serum level of mothers (Table 3). Compar-
ing P1GF serum values of the mother and umbilical 
vein, a positive and statistically significant correlation 
coefficient was obtained (r=0.4; p<0.05). A statistically 
significant correlation (r=0.34; p<0.05) between the 
placental weight and PlGF level of maternal serum was 
found too. It was found statistically significant differ-
ence between two groups in pH, pO2 and BE in blood 
of umbilical vein as well (Table 3).
Discussion
Vascular endothelial growth factor (VEGF) and pla-
cental growth factor (PlGF) are key factors in physiolog-
ical and pathological conditions. VEGF presents its ac-
tivity through its receptors (tyrosine kinase) VEGFR-1 
(Flt-1) and VEGFR-2 (KDR) which can be found in 
 endothelial cells.13–15 VEGF was localized on a tropho-
blast and macrophages of fetal and maternal origin. PlGF 
shows 53% of similarity with VEGF and is isolated from 
placenta and from media of bigger placental blood ves-
sels.14 PlGF presents its activity through its receptor 
VEGFR-1.
Two receptors, VEGFR-1 and VEGFR-2, are consid-
ered specific for endothelium. In placenta, endothelial 
and non-endothelial cells have VEGF receptors. VEGF 
is proved as a potent stimulator of the endothelial cell 
proliferation and creates plasminogen activator neces-
sary for proteolytic destruction. PlGF has been proved 
as a weak chemotaxis stimulator of endothelial cells 
and proliferation in a physiological concentration of 
<100ng/mL. VEGF also induces microvascular perme-
ability, while PlGF does not have any action, but inten-
sifies VEGF activity in small amounts.14,15 This different 
effect is explained by the fact that PlGF binds to VEG-
FR-1 but not to VEGF-2. By binding PlGF to VEGFR-1 
occurs a non-branching angiogenesis.16 VEGF and 
VEGFR-2 are high in early pregnancy and its concen-
tration decreases with the duration of pregnancy, while 
PlGF and VEGFR-1 at the same time increase. VEGF 
and VEGFR-2 are involved in the first two trimesters of 
pregnancy in forming the rich branching capillary net-
work of mesenchymal and immature villi, while PlGF 
and VEGFR-1 are involved in creating the long weakly 
branching terminal capillaries in the third trimester. 
VEGF stimulates extravasation of liquid and proteins; 
releases nitrate oxide.
In the first half of pregnancy there are only few pla-
cental villi, of a diameter of 170 µm. They are built of 
loose connective stroma which is on the outside covered 
by a two-layered trophoblast. Blood capillaries are 
small, situated in the central part of stroma, surrounded 
by stellate mesenchyme and Hofbauer’s cells. Basic 
functions of a placenta are carried out through placental 
membrane, which separates mothers from fetal blood. 
Till the 12th week of pregnancy a placental membrane is 
built of syncytiotrophoblast, cytotrophoblast, mesen-
chyme and endothelium of villous blood vessels. By 
budding of intermediary villi trophoblast, bases of new 
villi appear in which stroma soon grows in and branches 
of blood capillaries. In comparison with villi from pre-
vious stages of placental development, terminal villi are 
more numerous and of smaller diameter (about 70µm in 
the second and about 40µm in the third trimester of 
Table 3. Level of PlGF (pg/mL) in mothers serum and umbilical vein 
immediately after the birth and pH, pO2 and BE in umbilical artery 
blood.
Tablica 3. Razine PlGF (pg/mL) u maj~inom serumu i serumu vene um-


















PlGF in mother’s serum
PlGF u maj~inom serumu 249.6±193.1 178.0±191.0 n.s.
PlGF umbilical vein 
serum
PIGT u serumu 
umbilikalne vene
17.6±21,9 12.0±18,2 n.s.
pH umbilical vein blood
pH venske umbilikalne 
krvi
7.261±0.043 7.201±0.073 p=0.01
pO2 umbilical vein blood 
(kPa)
pO2 venske umbilikalne 
krvi (kPa)
4.12±1.38 2.62±0.90 p=0.001
Base excess in umbilical 
vein blood (mmol/L)





Gynaecol Perinatol 2010;19(1):10–15 Blaji} J. et al. Placental growth factor in mother’s and umbilical cord blood in pregnant women…
pregnancy). At the beginning of the second trimester, 
the number of cytotrophoblast and mesenchymal cells 
of stroma decreases and in the third trimester they most-
ly disappear.
The vascularisation of villi increases during pregnan-
cy, while the stroma quantity significantly decreases. At 
the end of pregnancy it is difficult to notice Hofbauer’s 
cells due to sinusoid dilatation of blood capillaries. In-
tercellular matter contains numerous collagen fibres 
which make the skeleton of the whole villus tree, from 
its basal part on a chorionic plate to the top of the small-
est terminal villus. However, there are significant differ-
ences in the quantity of intercellular matter of stroma 
and the distribution of its components, depending on the 
level of branching a villous tree.
In mature intermediary and terminal villi the quantity 
of intercellular matter of stroma is significantly lower, 
while fibres are mostly situated circularly, in a thin layer 
around blood capillaries.
PlGF level in a serum of healthy and diabetic preg-
nant women increases by four times from the first to the 
third trimester. This PlGF increase influences the growth 
of placenta and maintenance of adequate placental cir-
culation. After the 31st week of pregnancy of diabetic 
and healthy pregnant women, there is a decrease in 
PlGF level. In pregnant women with pre-eclampsia 
PlGF values in mother’s serum change insignificantly 
from the 30th week of pregnancy till birth.17 These val-
ues are lower than PlGF serum values of healthy preg-
nant women.17–21,25 These differences in PlGF level can 
be explained by the oxygen level in placenta. It is proved 
that oxygen is the main regulator of balance between 
VEGF and PlGF. Hypoxia increases VEGF activity, 
while hyperoxia decreases it. Successful placentation 
leads to the low resistance of blood vessels due to spiral 
artery transformation. Early development of placenta 
occurs in hypoxia conditions, which leads to stimula-
tion of cytotrophoblast proliferation and it inhibits tro-
phoblast invasion.22 The real blood flow is established 
between the 11th – 12th weeks of pregnancy. pO
2
 in-
creases and there is a trophoblast invasion as well as 
spiral artery changes, which leads to decreased resis-
tance in placenta. High oxygen level leads to slowing 
down of angiogenesis. Hypoxia leads to decrease of 
PlGF, mRNA and proteins. PlGF stimulates tropho-
blastic DNA synthesis in the first trimester and increas-
es the number of cells. In pregnant women with pre-ec-
lampsia, mother’s oxygenation is normal, but due to 
damages to uteroplacental circulation, placenta and fe-
tus are hypoxic. In these conditions VEGF increases 
and PlGF decreases.16,25 Comparing parameters of acid-
base condition of fetuses born by healthy pregnant 
women and diabetic pregnant women, there was a sig-
nificant difference in pH values, pO2 and BE. A more 
frequent chronic fetal hypoxia of diabetic fetuses might 
be the cause of lower (but not of statistically significant 
difference) PlGF vessels of mother, as well as of fetal 
development of blood vessels.
Since mother’s diabetes is quite a frequent complica-
tion in pregnancy, changes on a placenta result in values 
in fetal and mothers serum.
The correlation of PlGF serum value of a mother and 
umbilical vein confirm the hypothesis that PlGF influ-
ences the development of uteroplacental blood vessels 
of mother, as well as of fetal development of blood ves-
sels.
Placentas from pregnancies with badly supervised 
diabetes are enlarged, fat and plethoric due to fetal hy-
pervolemia and mother’s hyperglycemia.23 In cases of 
low glucose intolerance in pregnancy, it was established 
that a placental weight was also increased (as well as 
fetoplacental weight ratio),24 while in case of well su-
pervised glycemia level, the placental weight does not 
differ from the normal one.23
Regarding the findings on a placenta from pregnancy 
complicated by diabetes it can be concluded that its 
macroscopic and histological features primarily depend 
on the quality of glucose level regulation in mother’s 
blood and those changes which can be found in it are 
not specific, but are quite characteristic for diabetes.
Conclusions
PlGF increases from the beginning of pregnancy till 
the 31st week of pregnancy in both healthy and diabetic 
pregnant women, after which there is a decrease in PlGF 
values.
PlGF values in healthy and type-1 diabetes pregnant 
women do not differ in same weeks of pregnancy.
PlGF values in mother’s and fetal serum immediately 
after birth are a bit lower (but not statistically signifi-
cant) in diabetic pregnant women in relation to a control 
group.
A statistically significant correlation coefficient was 
found between PlGF level and a newborns weight and 
between PlGF and placenta weight.
A statistically significant correlation coefficient was 
found between PlGF level of mother’s serum and um-
bilical vein serum.
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